Composition: Ipratropim Bromide I.P. eqv. to Ipratropium Bromide anhydrous 20 mcg + Levo-Salbutamol Tartrate eqv. to Levo Salbutamol 50 mcg + Abs. Alchol 3.40% v/v

• Provides Longer duration of action and more reassuring safety profile than Ipratropium monotherapy.
• Shows additive action to produces greater bronchodilation.
• Free from cardiovascular complications which are generally present in high doses of beta-2 against drugs.

Indications:

• COPD
• Asthma
• Chronic Bronchitis